BCR::ABL1 TKIs are standard of care for all patients with CML and have transformed their outcome, with most patients presenting in first chronic phase having a near normal life expectancy [1]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.